第14届国际阿尔茨海默病与帕金森病大会 The 14th International Conference on Alzheimer's & Parkinson's Diseases, AD/PDTM 2019 AD/PDTM 2019

征稿已开启

已截稿

注册已开启

已截止

活动简介

第14届国际阿尔兹海默病和帕金森病大会会议 (The 14th International Conference on Alzheimer’s & Parkinson’s Diseases, AD/PDTM 2019) 将于2019年3月26日-- 31日在历史悠久、风光秀丽的欧洲名城葡萄牙首都里斯本举行。

AD/PDTM 2019大会自上世纪80年代首次举办以来，迄今已连续成功举办13届，成为国际上展示AD/PD及相关退行性疾病研究领域最新突破性进展的重要平台，在医学界、科学界和教育界受到了广泛的好评和普遍的赞誉。

本次大会主题：神经退行性疾病机理、临床策略和未来诊疗方法。参会者将包括众多临床医学工作者、基础医学和生命科学研究工作者、研究生等。上届参会人数达3,217人，预计本次会议参会人数将再创新高。大会荣幸地邀请到诺贝尔奖获得者T Sudof、A Ciechanover，2018 Brain Prize 获奖者B De Strooper、C Haass以及D Cleveland、D Selkoe 等104位国际基础和临床研究领域的著名学者。详情请见大会主页“Scientific Information”中“ meet the Faculty”一栏。

里斯本历史悠久，13世纪成为葡萄牙首都。在16世纪大航海时代，它是当时欧洲最兴盛的港口之一。市郊汇聚众多的博物馆及纪念碑，象征着葡萄牙帝国曾经闪耀的荣光。里斯本全年大部分时间风和日丽，温暖如春，鲜花盛开，宛如一座妩媚芬芳的大花园。整个城市依山傍水，远远望去，色调深浅不一的红瓦顶房屋和浓淡不同的绿色树丛交相辉映，景色十分优美。

征稿信息

Abstracts must be submitted via this website. Faxed or emailed abstracts will not be considered.

Please read the submission rules before submitting an abstract.

Please note each participant may present a maximum of 5 abstracts. There is no limit to the amount of abstracts one person may submit.

The system will count the amount of presentations from all submissions and notify you if the person you would like to assign as presenter has reached the maximum 5 presentations.

Submitters and co-authors can be listed on as many abstracts as needed.
The presenting author is required to ensure that all co-authors are aware of the content of the abstract before submission.
The presenting author must be listed as the first author.
Submitted abstracts should include non-published data.
Abstracts previously presented will not be accepted.
All abstracts should be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication. If you need help, please arrange for the review of your abstract by a colleague who is a native English speaker, by a university specific publications office (or other similar facility) or by a copy editor, prior to submission.
Please submit symbols as words.
All abstracts accepted for presentation will be published on the Conference website prior to the Conference.
You may submit more than 1 abstract. However, presenters that are accepted for oral presentation will be permitted to give only 1 oral presentation. Additional accepted abstracts will therefore be poster only.
The abstracts of the Conference will be published online as a supplement to the Neurodegenerative Diseases Journal (NDD) published by S. Karger AG (details to be confirmed)
Please note the submitting author will receive all correspondence about the abstract so we advise that the submitting author details that are entered are the same details as those of the presenting author.
Eligible candidates for Junior Faculty Awards are graduate students (PhD, MD) or junior scientists up to five years after the doctorate degree (PhD, MD.
Please ensure that if you are submitting an abstract to be considered for theJunior Faculty Award that you upload all relevant supporting documents via the link you will receive in the confirmation e-mail you receive once you final submit your abstract.
Abstracts may not be edited/updated after final submission. You are welcome to bring an updated abstract onsite with you.
Your abstract is not successfully submitted until you receive a confirmation e-mail after clicking the final submit button. If you do not receive a confirmation e-mail, please contact us.

征稿范围

Themes:	Topics:
Theme A: β-Amyloid Diseases	A1.a. Disease Mechanisms, Pathophysiology: Abeta aggregation, protein misfolding
	A1.b. Disease Mechanisms, Pathophysiology: Cell to cell transmission, spreading of pathology, prion-like
	A1.c. Disease Mechanisms, Pathophysiology: Inflammation
	A1.d. Disease Mechanisms, Pathophysiology: Synaptic plastcity & synapse pathology
	A1.e. Disease Mechanisms, Pathophysiology: Cellular signalling, kinases, phosphatases, calcium
	A1.f. Disease Mechanisms, Pathophysiology: Lysosomes, ubiquitin, proteasome, ER stress, chaperones
	A1.g. Disease Mechanisms, Pathophysiology: Mitochondrial dysfunction, oxidative damage
	A1.h. Disease Mechanisms, Pathophysiology: Lipids, lipoproteins and membrane trafficking
	A1.i. Disease Mechanisms, Pathophysiology: Microglia
	A1.j. Disease Mechanisms, Pathophysiology: Astroglia
	A1.k. Disease Mechanisms, Pathophysiology: Neurogenesis
	A1.l. Disease Mechanisms, Pathophysiology: Vasculature, microbleeds, hypertension, angiogenesis
	A1.m. Disease Mechanisms, Pathophysiology: Blood-brain barrier
	A1.n. Disease Mechanisms, Pathophysiology: Metabolism, insulin
	A1.o. Disease Mechanisms, Pathophysiology: Neural networks, plasticity
	A1.p. Disease Mechanisms, Pathophysiology: Transcriptional & translational regulation, micro RNAs
	A1.q. Disease Mechanisms, Pathophysiology: Autophagy, apoptosis, cell death
	A1.r. Disease Mechanisms, Pathophysiology: Aging
	A1.s. Disease Mechanisms, Pathophysiology: Microbiome
	A1.t. Disease Mechanisms, Pathophysiology: Other
	A2.a. Therapeutic Targets, Mechanisms for Treatment: Abeta, truncated & pGlu-Abeta
	A2.b. Therapeutic Targets, Mechanisms for Treatment: Immunotherapy
	A2.c. Therapeutic Targets, Mechanisms for Treatment: Secretases, proteases
	A2.d. Therapeutic Targets, Mechanisms for Treatment: Kinases, other enzymes
	A2.e. Therapeutic Targets, Mechanisms for Treatment: Neurotransmitters & receptor-based
	A2.f. Therapeutic Targets, Mechanisms for Treatment: ApoE & lipoprotein-based
	A2.g. Therapeutic Targets, Mechanisms for Treatment: Anti-inflammatory
	A2.h. Therapeutic Targets, Mechanisms for Treatment: Anti-oxidants
	A2.i. Therapeutic Targets, Mechanisms for Treatment: Neurotrophic, synaptic plasticity, repair, regenerative medicine
	A2.j. Therapeutic Targets, Mechanisms for Treatment: Protein aggregation, misfolding, chaperones
	A2.k. Therapeutic Targets, Mechanisms for Treatment: TREM2
	A2.l. Therapeutic Targets, Mechanisms for Treatment: CD33
	A2.m. Therapeutic Targets, Mechanisms for Treatment: Microglia
	A2.n. Therapeutic Targets, Mechanisms for Treatment: Astroglia
	A2.o. Therapeutic Targets, Mechanisms for Treatment: Gene therapy and gene editing
	A2.p. Therapeutic Targets, Mechanisms for Treatment: ASO and RNAi
	A2.q. Therapeutic Targets, Mechanisms for Treatment: neurogenesis and iPSC
	A2.r. Therapeutic Targets, Mechanisms for Treatment: Other
	A3.a. Drug Development, Clinical Trials: Immunotherapy
	A3.b. Drug Development, Clinical Trials: Immunomodulators
	A3.c. Drug Development, Clinical Trials: Amyloid clearance
	A3.d. Drug Development, Clinical Trials: Secretase inhibitors & modulators
	A3.e. Drug Development, Clinical Trials: Aggregation inhibitors
	A3.f. Drug Development, Clinical Trials: Neuroprotective & mitochondrial compounds
	A3.g. Drug Development, Clinical Trials: Neurotransmitter-based modulators
	A3.h. Drug Development, Clinical Trials: Receptor ligands
	A3.i. Drug Development, Clinical Trials: Mitochondrial drugs
	A3.j. Drug Development, Clinical Trials: Cell-based therapies
	A3.k. Drug Development, Clinical Trials: Transcranial magnetic stimulation
	A3.l. Drug Development, Clinical Trials: Medicinal chemistry approaches, drug repurposing
	A3.m. Drug Development, Clinical Trials: Personalized medicines
	A3.n. Drug Development, Clinical Trials: Regulatory aspects
	A3.o. Drug Development, Clinical Trials: Non-pharmacological interventions
	A3.p. Drug Development, Clinical Trials: Other
	A4.a. Imaging, Biomarkers, Diagnostics: Structural MRI, MR spectroscopy
	A4.b. Imaging, Biomarkers, Diagnostics: Functional MRI
	A4.c. Imaging, Biomarkers, Diagnostics: PET - amyloid
	A4.d. Imaging, Biomarkers, Diagnostics: PET - glucose
	A4.e. Imaging, Biomarkers, Diagnostics: PET - other
	A4.f. Imaging, Biomarkers, Diagnostics: SPECT
	A4.g. Imaging, Biomarkers, Diagnostics: Multimodal imaging
	A4.h. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers
	A4.i. Imaging, Biomarkers, Diagnostics: EEG, brain mapping, MEG
	A4.j. Imaging, Biomarkers, Diagnostics: Cognitive, psychometric & behavioral tests
A4.k. Imaging, Biomarkers, Diagnostics: Other
A5.a. Genetics, Epidemiology: Whole genome sequencing
A5.b. Genetics, Epidemiology: Disease-causing mutations
A5.c. Genetics, Epidemiology: GWAS, genetic associations, susceptibility & protective genes
A5.e. Genetics, Epidemiology: Aging
A5.f. Genetics, Epidemiology: Environmental risk factors
A5.g. Genetics, Epidemiology: Metabolic and cardiovascular
A5.h. Genetics, Epidemiology: Infectious and inflammation
A5.i. Genetics, Epidemiology: Other
A6.a. Cell, Molecular and Systems Biology: APP, APLP, Abeta
A6.b. Cell, Molecular and Systems Biology: ApoE
A6.c. Cell, Molecular and Systems Biology: Secretases
A6.d. Cell, Molecular and Systems Biology: Growth factors, synaptic plasticity
A6.e. Cell, Molecular and Systems Biology: GCPR, nicotinic, sigma-1 & other receptors
A6.f. Cell, Molecular and Systems Biology: Network biology, connectome, protein-protein interations
A6.g. Cell, Molecular and Systems Biology: Metabolomics, transcriptomics, lipidomics, proteomics
A6.h. Cell, Molecular and Systems Biology: Epigenetics, histone modification, DNA methylation
A6.i. Cell, Molecular and Systems Biology: Other
A7.a. Animal Models: Transgenic rodents
A7.b. Animal Models: Primates, naturally occuring models
A7.c. Animal Models: Non-mamalian models
A7.d. Animal Models: Optogenetics
A7.e. Animal Models: Other
Theme B: Taupathies	B1.a. Disease Mechanisms, Pathophysiology: Tau aggregation, phophorylation, acetylation & modifications
	B1.b. Disease Mechanisms, Pathophysiology: Cell to cell transmission, spreading of pathology, prion-like
	B1.c. Disease Mechanisms, Pathophysiology: Inflammation
	B1.d. Disease Mechanisms, Pathophysiology: Synapse pathology
	B1.e. Disease Mechanisms, Pathophysiology: Cellular signalling, kinases, phosphatases, calcium
	B1.f. Disease Mechanisms, Pathophysiology: Lysosomes, ubiquitin, proteasome, ER stress
	B1.g. Disease Mechanisms, Pathophysiology: Mitochondrial dysfunction, oxidative damage
	B1.h. Disease Mechanisms, Pathophysiology: Lipids, lipoproteins and membrane trafficking
	B1.i. Disease Mechanisms, Pathophysiology: Microglia
	B1.j. Disease Mechanisms, Pathophysiology: Astroglia
	B1.k. Disease Mechanisms, Pathophysiology: Neurogenesis
	B1.l. Disease Mechanisms, Pathophysiology: Vasculature, angiogenesis
	B1.m. Disease Mechanisms, Pathophysiology: Blood-brain barrier
	B1.n. Disease Mechanisms, Pathophysiology: Metabolism, insulin
	B1.o. Disease Mechanisms, Pathophysiology: Neural networks & plasticity
	B1.p. Disease Mechanisms, Pathophysiology: transcriptional & translational regulation, micro RNAs
	B1.q. Disease Mechanisms, Pathophysiology: Autophagy, apoptosis, cell death
	B1.r. Disease Mechanisms, Pathophysiology: Protein misfolding, chaperones
	B1.s. Disease Mechanisms, Pathophysiology: Aging
	B1.t. Disease Mechanisms, Pathophysiology: Microbiome
	B1.u. Disease Mechanisms, Pathophysiology: Other
	B2.a. Therapeutic Targets, Mechanisms for Treatment: Tau, phosphorylation, truncation
	B2.b. Therapeutic Targets, Mechanisms for Treatment: Immunotherapy
	B2.c. Therapeutic Targets, Mechanisms for Treatment: Kinases, phosphatases, other enzymes
	B2.d. Therapeutic Targets, Mechanisms for Treatment: Neurotransmitters & receptor-based
	B2.e. Therapeutic Targets, Mechanisms for Treatment: Anti-inflammatory
	B2.f. Therapeutic Targets, Mechanisms for Treatment: Anti-oxidants
	B2.g. Therapeutic Targets, Mechanisms for Treatment: Neurotrophic, synaptic plasticity, repair
	B2.h. Therapeutic Targets, Mechanisms for Treatment: Protein aggregation, NFT, misfolding, chaperones
	B2.i. Therapeutic Targets, Mechanisms for Treatment: Gene and RNAi therapy
	B2.j. Therapeutic Targets, Mechanisms for Treatment: Microglia
	b2.k. Therapeutic Targets, Mechanisms for Treatment: Astroglia
	B2.l. Therapeutic Targets, Mechanisms for Treatment: Adult neurogenesis
	B2.m. Therapeutic Targets, Mechanisms for Treatment: Other
	B3.a. Drug Development, Clinical Trials: Immunotherapy
	B3.b. Drug Development, Clinical Trials: Immunomodulators
	B3.c. Drug Development, Clinical Trials: tau clearance
	B3.d. Drug Development, Clinical Trials: Kinase inhibitors & phosphatase modulators
	B3.e. Drug Development, Clinical Trials: Aggregation inhibitors
	B3.f. Drug Development, Clinical Trials: Neuroprotective & mitochondrial compounds
	B3.g. Drug Development, Clinical Trials: Neurotransmitter-based modulators
	B3.h. Drug Development, Clinical Trials: Mitochondrial drugs
	B3.i. Drug Development, Clinical Trials: Cell-based therapies
	B3.j. Drug Development, Clinical Trials: Transcranial magnetic stimulation
	B3.k. Drug Development, Clinical Trials: Personalized medicines
	B3.l. Drug Development, Clinical Trials: Regulatory aspects
	B3.m. Drug Development, Clinical Trials: Medicinal chemistry approaches, drug repurposing
	B3.n. Drug Development, Clinical Trials: Non-pharmacological interventions
	B3.o. Drug Development, Clinical Trials: Other
	B4.a. Imaging, Biomarkers, Diagnostics: Structural MRI, MR spectroscopy
	B4.b. Imaging, Biomarkers, Diagnostics: Functional MRI
	B4.c. Imaging, Biomarkers, Diagnostics: PET - tau
	B4.d. Imaging, Biomarkers, Diagnostics: PET - glucose
	B4.e. Imaging, Biomarkers, Diagnostics: PET - other
	B4.f. Imaging, Biomarkers, Diagnostics: SPECT
	B4.g. Imaging, Biomarkers, Diagnostics: Multimodal imaging
	B4.h. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers
	B4.i. Imaging, Biomarkers, Diagnostics: EEG, brain mapping, MEG
	B4.j. Imaging, Biomarkers, Diagnostics: Cognitive, psychometric & behavioral tests
	B4.k. Imaging, Biomarkers, Diagnostics: Other
	B5.a. Genetics, Epidemiology: Whole genome sequencing
	B5.b. Genetics, Epidemiology: Disease-causing mutations
	B5.c. Genetics, Epidemiology: GWAS, genetic associations, susceptibility & protective genes
	B5.d. Genetics, Epidemiology: Aging
B5.e. Genetics, Epidemiology: Environmental risk factors
B5.f. Genetics, Epidemiology: Metabolic, cardiovascular, inflammation
B5.g. Genetics, Epidemiology: Other
B6.a. Cell, Molecular and Systems Biology: Tau, tau isoforms
B6.b. Cell, Molecular and Systems Biology: Kinases, phosphatases
B6.c. Cell, Molecular and Systems Biology: Posttranslational modifications
B6.d. Cell, Molecular and Systems Biology: Growth factors, synaptic plasticity
B6.e. Cell, Molecular and Systems Biology: GCPR, nicotinic, sigma-1, other receptors
B6.f. Cell, Molecular and Systems Biology: Network biology, connectome, protein-protein interations
B6.g. Cell, Molecular and Systems Biology: Metabolomics, transcriptomics, lipidomics, proteomics
B6.h. Cell, Molecular and Systems Biology: Epigenetics, histone modification, DNA methylation
B4.k. Cell, Molecular and Systems Biology: Other
B7.a. Animal Models: Transgenic rodents
B7.b. Animal Models: Primates, naturally occuring models
B7.c. Animal Models: Non-mamalian models
B7.d. Animal Models: Optogenetics
B7.3. Animal Models: Other
Theme C: α-Synucleinopathies	C1.a. Disease Mechanisms, Pathophysiology: Α-synuclein aggregation
	C1.b. Disease Mechanisms, Pathophysiology: LRKK2, parkin, PINK1, DJ-1
	C1.c. Disease Mechanisms, Pathophysiology: Cell to cell transmission, spreading of pathology, prion-like
	C1.d. Disease Mechanisms, Pathophysiology: Autophagy, lysosomes, ubiquitin, proteasome
	C1.e. Disease Mechanisms, Pathophysiology: Lipids, lipoproteins and membrane trafficking
	C1.f. Disease Mechanisms, Pathophysiology: Inflammation
	C1.g. Disease Mechanisms, Pathophysiology: Microglia
	C1.h. Disease Mechanisms, Pathophysiology: Astroglia
	C1.i. Disease Mechanisms, Pathophysiology: Cellular signalling, kinases, phosphatases, calcium
	C1.i. Disease Mechanisms, Pathophysiology: Mitochondrial dysfunction, oxidative damage
	C1.j. Disease Mechanisms, Pathophysiology: Vasculature, angiogenesis, blood-brain barrier
	C1.k. Disease Mechanisms, Pathophysiology: Synapse pathology, neural networks, plasticity, neurogenesis
	C1.l. Disease Mechanisms, Pathophysiology: Transcriptional & translational regulation, micro RNAs
	C1.m. Disease Mechanisms, Pathophysiology: apoptosis, cell death
	C1.n. Disease Mechanisms, Pathophysiology: Protein aggregation, misfolding, chaperones
	C1.o. Disease Mechanisms, Pathophysiology: Metal ions
	C1.p. Disease Mechanisms, Pathophysiology: Modeling of disease progression
	C1.q. Disease Mechanisms, Pathophysiology: Other
	C2.a. Therapeutic Targets, Mechanisms for Treatment: Α-synuclein
	C2.b. Therapeutic Targets, Mechanisms for Treatment: Immunotherapy
	C2.c. Therapeutic Targets, Mechanisms for Treatment: Kinases, other enzymes
	C2.d. Therapeutic Targets, Mechanisms for Treatment: Dopamine, neurotransmitters
	C2.e. Therapeutic Targets, Mechanisms for Treatment: Cell transplantation
	C2.f. Therapeutic Targets, Mechanisms for Treatment: Deep brain stimulation
	C2.g. Therapeutic Targets, Mechanisms for Treatment: Anti-inflammatory, anti-oxidant
	C2.h. Therapeutic Targets, Mechanisms for Treatment: Microglia
	C2.i. Therapeutic Targets, Mechanisms for Treatment:Astroglia
	C2.j. Therapeutic Targets, Mechanisms for Treatment: Protein aggregation, misfolding, chaperones
	C2.k. Therapeutic Targets, Mechanisms for Treatment: Gene therapy and gene editing
	C2.l. Therapeutic Targets, Mechanisms for Treatment: ASO and RNAi
	C2.m. Therapeutic Targets, Mechanisms for Treatment: neurogenesis and iPSC
	C2.n. Therapeutic Targets, Mechanisms for Treatment: Other
	C3.a. Drug Development, Clinical Trials: Immunotherapy
	C3.b. Drug Development, Clinical Trials: Vitamins, antioxidants, neuroprotective compounds
	C3.c. Drug Development, Clinical Trials: Neurotransmitter- and receptor based modulators
	C3.d. Drug Development, Clinical Trials: Deep brain stimulation
	C3.e. Drug Development, Clinical Trials: Aggregation inhibitors
	C3.f. Drug Development, Clinical Trials: Enzyme modulators
	C3.g. Drug Development, Clinical Trials: Medicinal chemistry approaches, drug repurposing
	C3.h. Drug Development, Clinical Trials: Drug delivery systems
	C3.i. Drug Development, Clinical Trials: Non-pharmacological interventions, neurosurgery
	C3.j. Drug Development, Clinical Trials: Microbiome
	C3.k. Drug Development, Clinical Trials: Other
	C4.a. Imaging, Biomarkers, Diagnostics: Structural MRI, MR spectroscopy
	C4.b. Imaging, Biomarkers, Diagnostics: Functional MRI
	C4.c. Imaging, Biomarkers, Diagnostics: PET
	C4.d. Imaging, Biomarkers, Diagnostics: SPECT
	C4.e. Imaging, Biomarkers, Diagnostics: Multimodal imaging
	C4.f. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers
	C4.g. Imaging, Biomarkers, Diagnostics: EEG, brain mapping, MEG
	C4.h. Imaging, Biomarkers, Diagnostics: Cognitive, psychometric, behavioral and motor tests
	C4.i. Imaging, Biomarkers, Diagnostics: Microbiome
	C4.j. Imaging, Biomarkers, Diagnostics: Other
	C5.a. Genetics, Epidemiology: Whole genome sequencing
	C5.b. Genetics, Epidemiology: Disease-causing mutations
	C5.c. Genetics, Epidemiology: GWAS, genetic associations, susceptibility & protective genes
	C5.d. Genetics, Epidemiology: Aging
	C5.e. Genetics, Epidemiology: Environmental risk factors
	C5.f. Genetics, Epidemiology: Inflammation
	C5.g. Genetics, Epidemiology: Other
	C6.a. Cell, Molecular and Systems Biology: Α-synuclein
	C6.b. Cell, Molecular and Systems Biology: LRKK2, parkin, PINK1, DJ-1 and other PD realted genes
	C6.c. Cell, Molecular and Systems Biology: Growth factors, synaptic plasticity
	C6.d. Cell, Molecular and Systems Biology: GCPR, dopamine & other receptors
C6.e. Cell, Molecular and Systems Biology: Network biology, connectome, protein-protein interations
C6.f. Cell, Molecular and Systems Biology: Metabolomics, transcriptomics, lipidomics, proteomics
C6.g. Cell, Molecular and Systems Biology: Epigenetics, histone modification, DNA methylation
C6.h. Cell, Molecular and Systems Biology: Other
C7.a. Animal Models: Transgenic rodents
C7.b. Animal Models: Primates, naturally occuring models
C7.c. Animal Models: Non-mamalian models
C7.d. Animal Models: Optogenetics
C7.e. Animal Models: Other
Theme D: TDP43- and C9orf72-Related Diseases	D1. Disease Mechanisms, Pathophysiology
	D2. Therapeutic Targets, Mechanisms for Treatment
	D3. Drug Development, Clinical Trials
	D4. Imaging, Biomarkers, Diagnostics
	D5. Genetics, Epidemiology
	D6. Cell, Molecular and Systems Biology
	D7. Animal Models
Theme E : Vascular Diseases	E1. Disease Mechanisms, Pathophysiology
	E2. Therapeutic Targets, Mechanisms for Treatment
	E3. Drug Development, Clinical Trials
	E4. Imaging, Biomarkers, Diagnostics
	E5. Genetics, Epidemiology
	E6. Cell, Molecular and Systems Biology
	E7. Animal Models
Theme F: Prion Diseases	F1. Disease Mechanisms, Pathophysiology
	F2. Therapeutic Targets, Mechanisms for Treatment
	F3. Drug Development, Clinical Trials
	F4. Imaging, Biomarkers, Diagnostics
	F5. Genetics, Epidemiology
	F6. Cell, Molecular and Systems Biology
	F7. Animal Models
Theme G: Huntington's and Other Neurodegenerative Diseases	G1. Disease Mechanisms, Pathophysiology
	G2. Therapeutic Targets, Mechanisms for Treatment
	G3. Drug Development, Clinical Trials
	G4. Imaging, Biomarkers, Diagnostics
	G5. Genetics, Epidemiology
	G6. Cell, Molecular and Systems Biology
	G7. Animal Models
Theme H: Demyelinating Diseases	H1. Disease Mechanisms, Pathophysiology
	H2. Therapeutic Targets, Mechanisms for Treatment
	H3. Drug Development, Clinical Trials
	H4. Imaging, Biomarkers, Diagnostics
	H5. Genetics, Epidemiology
	H6. Cell, Molecular and Systems Biology
	H7. Animal Models
Theme I: Lysosomal Storage Diseases	I1. Disease Mechanisms, Pathophysiology
	I2. Therapeutic Targets, Mechanisms for Treatment
	I3. Drug Development, Clinical Trials
	I4. Imaging, Biomarkers, Diagnostics
	I5. Genetics, Epidemiology
	I6. Cell, Molecular and Systems Biology
	I7. Animal Models
Theme J: Psychiatric Symptoms in Neurodegenerative Diseases	J1. Disease Mechanisms, Pathophysiology
	J2. Therapeutic Targets, Mechanisms for Treatment
	J3. Drug Development, Clinical Trials
	J4. Imaging, Biomarkers, Diagnostics
	J5. Genetics, Epidemiology
	J6. Cell, Molecular and Systems Biology
	J7. Animal Models
Theme K: Patient Care and Support	K1.a. Dementia and Cognitive Dyfunction: Caregiver support
	K1.b. Dementia and Cognitive Dyfunction: Mobile applications, social networks
	K1.c. Dementia and Cognitive Dyfunction: Cognitive training
	K1.d. Dementia and Cognitive Dyfunction: Exercise
	K1.e. Dementia and Cognitive Dyfunction: Support devices & monitoring
	K1.f. Dementia and Cognitive Dyfunction: Quality of life
	K1.g. Dementia and Cognitive Dyfunction: Functional foods
	K1.h. Dementia and Cognitive Dyfunction: Behavioral & psychiatric symptoms
	K1.i. Dementia and Cognitive Dyfunction: Fall prevention & patient protection
	K1.j. Dementia and Cognitive Dyfunction: Other
	K2.a. Movement Disorders: Caregiver support
	K2.b. Movement Disorders: Mobile applications, social networks
	K2.c. Movement Disorders: Motor coordination & exercise
	K2.d. Movement Disorders: Support devices & monitoring
	K2.e. Movement Disorders: Functional foods
	K2.f. Movement Disorders: Quality of life
	K2.g. Movement Disorders: Fall prevention & patient protection
	K2.g. Movement Disorders: Behavioral & psychiatric symptoms
	K2.h. Movement Disorders: Other